We, therefore, hypothesized that the characterization of a common ErbB co-regulon might identify co-regulated and potentially co-druggable targets or response biomarkers for future multimodal precision therapy in head and neck squamous cell carcinoma. Here, EGFR is linked to head and neck squamous cell carcinoma.